SlideShare a Scribd company logo
A Budget Impact Analysis of Alirocumab in Heterozygous Familial
Hypercholesterolemia Treatment
Background:
Heterozygous familial hypercholesterolemia (HeFH) is a rare genetic disease affecting an
estimated 1:500 people. The disease results in LDL levels far above the recommended
range which results in an increased risk of adverse cardiac events. Current standard of
care treatment options such as high intensity statins and ezetimibe, only achieve
recommended LDL levels, instituted by ATP III guidelines, in 20% of treated
patients.PKSC9 inhibitors are a new class of effective but highly priced drug therapy
recently approved to treat HeFH that have been shown to be safe and more effective in
lowering LDL to guideline recommended levels.
Objective:
The aim of this study was to prepare a budget impact analysis based on pharmacy drug
costs only, as outcomes data was not yet available, to assist a commercial health plan in
evaluating the 1 year financial impact of the introduction of Alirocumab to their
formulary for the approved treatment of Heterozygous Familial Hypercholesterolemia.
Methods:
A budget impact analysis was developed for a hypothetical commercial US health plan
consisting of 1 million members ages 18-64 years old. Data was inputted into a model
created in an excel spreadsheet. Model inputs included disease prevalence reported from
the center for disease control, target population, drug costs obtained from whole sale
acquisition costs from Red Book (accessed June 2015), and estimated drug market shares
based on treatment guidelines and efficacy data. Costs were reported in 2015 US dollars
as total overall costs, price per member per month (PMPM), and price per treated
member per month (PTMPM). A One-Way sensitivity analysis was performed on the
study assumptions which included the costs of the new treatment and the already
established medications for treatment, and the percentage of patients treated.
Results:
An estimated 1,600 of the hypothetical 1,000,000 enrollees were projected to be treated
for heterozygous familial hypercholesterolemia. It was estimated based on current
treatment data, that 70% or 1,120 enrollees would be placed on Alirocumab due to lack
of meeting ATP III LDL goals by current basic standard of care treatments. Statistical
analysis was done on drug costs only. It was found that the addition of Alricoumab as a
treatment option resulted in a total drug spend of $11,712,160 over a 1 year time horizon.
The estimated PMPM for all covered lives was $0.976 while the estimated PTMPM for
all covered lives was $7,320. Based on the sensitivity analysis, the PMPM after the
introduction of Alirocumab had a range $0.883-$1.074 and the range for PTMPM was
$6,954-$7,686.
Conclusion:
Alirocumab has been proven by multiple double blind, placebo, controlled clinical trials
to be safe and effective with 94% of patients treated achieving LDL levels less than
100mg/dL. It is an effective treatment option for patients who are not achieving their
LDL goals on a high intensity statin with or without ezetimibe. However, the high
projected cost of $10,000 for a one year of treatment with alirocumab will need to be
heavily weighed when making formulary decisions. A better analysis will be able to be
formed when data from the ODYSSEY OUTCOMES trial is released in 2017.
Bibliography
Eur Heart J. 2013 Dec 1; 34(45): 3478–3490.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3844152/
"Gene Mutations Linked to Statin Resistance." <i>- Duke Medicine</i>. Duke Medicine
News and Communications, 4 Aug. 2010. Web. 01 July 2015.
FDA advisory committee briefing document PraluentTM (alirocumab). Endocrinologic
and Metabolic Drugs Advisory Committee.
http://amcp.edossiers.com/students/search/ext_preview.aspx?ModuleID=5100&ItemID=
1984282&DrugID=6755&From=RES June 9, 2015
Kastelein, John J. P., Jennifer G. Robinson, Michel Farnier, Michel Krempf, Gisle
Langslet, Christelle Lorenzato, Daniel A. Gipe, and Marie T. Baccara-Dinet. "Efficacy
and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia
Not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale
of the ODYSSEY FH Studies." Cardiovascular Drugs and Therapy. Springer US, 20
May 2014. Web. 01 July 2015.
Pijlman, A.H. et al. “Evaluation of cholesterol lowering treatment of patients with
familial hypercholesterolemia: a large cross-sectional study in The Netherlands
Atherosclerosis , Volume 209 , Issue 1 , 189 – 194
Red Book Online, Micromedex Solutions. Accessed June, 2015
Straton, Tracy. "Payers Fret about the next Drug Doomsday: Pricey PCSK9 Cholesterol
Meds." FiercePharmaMarketing. Fierce Pharma Marketing, 7 May 2014. Web. 01 July
2015.

More Related Content

What's hot

Corticosteroids in severe asthma JMCP
Corticosteroids in severe asthma JMCPCorticosteroids in severe asthma JMCP
Corticosteroids in severe asthma JMCPLaurence Gozalo
 
Asn2010 Pd Medicare 8 Nov10
Asn2010 Pd Medicare 8 Nov10Asn2010 Pd Medicare 8 Nov10
Asn2010 Pd Medicare 8 Nov10
kyori1975
 
Stephen Wood: "The Role of Providers in the Opioid Epidemic"
Stephen Wood: "The Role of Providers in the Opioid Epidemic"Stephen Wood: "The Role of Providers in the Opioid Epidemic"
Stephen Wood: "The Role of Providers in the Opioid Epidemic"
The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics
 
Medicines optimisation, pop up uni, 9am, 3 september 2015
Medicines optimisation, pop up uni, 9am, 3 september 2015Medicines optimisation, pop up uni, 9am, 3 september 2015
Medicines optimisation, pop up uni, 9am, 3 september 2015
NHS England
 
Preliminary study of Prescription audit for evaluation of prescribing pattern...
Preliminary study of Prescription audit for evaluation of prescribing pattern...Preliminary study of Prescription audit for evaluation of prescribing pattern...
Preliminary study of Prescription audit for evaluation of prescribing pattern...
SriramNagarajan16
 
CMS-Proposed Antibiotic Stewardship Rules: What You Need to Know
CMS-Proposed Antibiotic Stewardship Rules: What You Need to KnowCMS-Proposed Antibiotic Stewardship Rules: What You Need to Know
CMS-Proposed Antibiotic Stewardship Rules: What You Need to Know
PYA, P.C.
 
The Effect of Computer-assisted Prescription in Critical Care Unit
The Effect of Computer-assisted Prescription in Critical Care Unit The Effect of Computer-assisted Prescription in Critical Care Unit
The Effect of Computer-assisted Prescription in Critical Care Unit
Mandirola, Humberto
 
Quality evaluation of community pharmacy blood pressure (BP) screening servic...
Quality evaluation of community pharmacy blood pressure (BP) screening servic...Quality evaluation of community pharmacy blood pressure (BP) screening servic...
Quality evaluation of community pharmacy blood pressure (BP) screening servic...
RavinaBarrett
 
Dyfrig hughes che presentation 15 1 2014
Dyfrig hughes che presentation 15 1 2014Dyfrig hughes che presentation 15 1 2014
Dyfrig hughes che presentation 15 1 2014cheweb1
 
Developing and Paying for Gene Therapies: Can We Resolve the Conflicts? A Eur...
Developing and Paying for Gene Therapies: Can We Resolve the Conflicts? A Eur...Developing and Paying for Gene Therapies: Can We Resolve the Conflicts? A Eur...
Developing and Paying for Gene Therapies: Can We Resolve the Conflicts? A Eur...
Office of Health Economics
 
Wielding the Double-Edge Sword of Cardiac Biomarkers in Clinical Trials: A Di...
Wielding the Double-Edge Sword of Cardiac Biomarkers in Clinical Trials: A Di...Wielding the Double-Edge Sword of Cardiac Biomarkers in Clinical Trials: A Di...
Wielding the Double-Edge Sword of Cardiac Biomarkers in Clinical Trials: A Di...
Medpace
 
Pharmacoepidemiology
PharmacoepidemiologyPharmacoepidemiology
Pharmacoepidemiology
Shaikh Abusufyan
 
The Cancer Drugs Fund in practice, under the new framework
The Cancer Drugs Fund in practice, under the new frameworkThe Cancer Drugs Fund in practice, under the new framework
The Cancer Drugs Fund in practice, under the new framework
Alex Diamantopoulos
 
Internal 2013 - General practice clinical systems
Internal 2013 - General practice clinical systemsInternal 2013 - General practice clinical systems
Internal 2013 - General practice clinical systems
Evangelos Kontopantelis
 
Pharmacoeconomics
PharmacoeconomicsPharmacoeconomics
Pharmacoeconomics
Santhi Dasari
 
Is willingness to pay higher for cancer prevention and treatment?
Is willingness to pay higher for cancer prevention and treatment?Is willingness to pay higher for cancer prevention and treatment?
Is willingness to pay higher for cancer prevention and treatment?
Office of Health Economics
 
Diabetes Care Journal
Diabetes Care JournalDiabetes Care Journal
Diabetes Care JournalPooja Oza
 
Gene Profiling in Clinical Oncology - Slide 12 - N. Liebermann - But can my h...
Gene Profiling in Clinical Oncology - Slide 12 - N. Liebermann - But can my h...Gene Profiling in Clinical Oncology - Slide 12 - N. Liebermann - But can my h...
Gene Profiling in Clinical Oncology - Slide 12 - N. Liebermann - But can my h...European School of Oncology
 
Establishing a Fair Price for an Orphan Drug by Mikel Berdud et al.
Establishing a Fair Price for an Orphan Drug by Mikel Berdud et al.Establishing a Fair Price for an Orphan Drug by Mikel Berdud et al.
Establishing a Fair Price for an Orphan Drug by Mikel Berdud et al.
Office of Health Economics
 

What's hot (20)

Corticosteroids in severe asthma JMCP
Corticosteroids in severe asthma JMCPCorticosteroids in severe asthma JMCP
Corticosteroids in severe asthma JMCP
 
Asn2010 Pd Medicare 8 Nov10
Asn2010 Pd Medicare 8 Nov10Asn2010 Pd Medicare 8 Nov10
Asn2010 Pd Medicare 8 Nov10
 
Stephen Wood: "The Role of Providers in the Opioid Epidemic"
Stephen Wood: "The Role of Providers in the Opioid Epidemic"Stephen Wood: "The Role of Providers in the Opioid Epidemic"
Stephen Wood: "The Role of Providers in the Opioid Epidemic"
 
Medicines optimisation, pop up uni, 9am, 3 september 2015
Medicines optimisation, pop up uni, 9am, 3 september 2015Medicines optimisation, pop up uni, 9am, 3 september 2015
Medicines optimisation, pop up uni, 9am, 3 september 2015
 
Preliminary study of Prescription audit for evaluation of prescribing pattern...
Preliminary study of Prescription audit for evaluation of prescribing pattern...Preliminary study of Prescription audit for evaluation of prescribing pattern...
Preliminary study of Prescription audit for evaluation of prescribing pattern...
 
CMS-Proposed Antibiotic Stewardship Rules: What You Need to Know
CMS-Proposed Antibiotic Stewardship Rules: What You Need to KnowCMS-Proposed Antibiotic Stewardship Rules: What You Need to Know
CMS-Proposed Antibiotic Stewardship Rules: What You Need to Know
 
The Effect of Computer-assisted Prescription in Critical Care Unit
The Effect of Computer-assisted Prescription in Critical Care Unit The Effect of Computer-assisted Prescription in Critical Care Unit
The Effect of Computer-assisted Prescription in Critical Care Unit
 
Quality evaluation of community pharmacy blood pressure (BP) screening servic...
Quality evaluation of community pharmacy blood pressure (BP) screening servic...Quality evaluation of community pharmacy blood pressure (BP) screening servic...
Quality evaluation of community pharmacy blood pressure (BP) screening servic...
 
Dyfrig hughes che presentation 15 1 2014
Dyfrig hughes che presentation 15 1 2014Dyfrig hughes che presentation 15 1 2014
Dyfrig hughes che presentation 15 1 2014
 
Developing and Paying for Gene Therapies: Can We Resolve the Conflicts? A Eur...
Developing and Paying for Gene Therapies: Can We Resolve the Conflicts? A Eur...Developing and Paying for Gene Therapies: Can We Resolve the Conflicts? A Eur...
Developing and Paying for Gene Therapies: Can We Resolve the Conflicts? A Eur...
 
Wielding the Double-Edge Sword of Cardiac Biomarkers in Clinical Trials: A Di...
Wielding the Double-Edge Sword of Cardiac Biomarkers in Clinical Trials: A Di...Wielding the Double-Edge Sword of Cardiac Biomarkers in Clinical Trials: A Di...
Wielding the Double-Edge Sword of Cardiac Biomarkers in Clinical Trials: A Di...
 
Pharmacoepidemiology
PharmacoepidemiologyPharmacoepidemiology
Pharmacoepidemiology
 
The Cancer Drugs Fund in practice, under the new framework
The Cancer Drugs Fund in practice, under the new frameworkThe Cancer Drugs Fund in practice, under the new framework
The Cancer Drugs Fund in practice, under the new framework
 
Internal 2013 - General practice clinical systems
Internal 2013 - General practice clinical systemsInternal 2013 - General practice clinical systems
Internal 2013 - General practice clinical systems
 
Pharmacoeconomics
PharmacoeconomicsPharmacoeconomics
Pharmacoeconomics
 
Is willingness to pay higher for cancer prevention and treatment?
Is willingness to pay higher for cancer prevention and treatment?Is willingness to pay higher for cancer prevention and treatment?
Is willingness to pay higher for cancer prevention and treatment?
 
Diabetes Care Journal
Diabetes Care JournalDiabetes Care Journal
Diabetes Care Journal
 
PtCS_Demo_Sales_v2016.3
PtCS_Demo_Sales_v2016.3PtCS_Demo_Sales_v2016.3
PtCS_Demo_Sales_v2016.3
 
Gene Profiling in Clinical Oncology - Slide 12 - N. Liebermann - But can my h...
Gene Profiling in Clinical Oncology - Slide 12 - N. Liebermann - But can my h...Gene Profiling in Clinical Oncology - Slide 12 - N. Liebermann - But can my h...
Gene Profiling in Clinical Oncology - Slide 12 - N. Liebermann - But can my h...
 
Establishing a Fair Price for an Orphan Drug by Mikel Berdud et al.
Establishing a Fair Price for an Orphan Drug by Mikel Berdud et al.Establishing a Fair Price for an Orphan Drug by Mikel Berdud et al.
Establishing a Fair Price for an Orphan Drug by Mikel Berdud et al.
 

Viewers also liked

The Interactive Education Story
The Interactive Education StoryThe Interactive Education Story
The Interactive Education Story
Nik Spittle
 
Traditional game of bangladesh
Traditional game of bangladeshTraditional game of bangladesh
Traditional game of bangladesh
Sayem Al Nahian
 
Cape Cod Web Technology Meetup - 3
Cape Cod Web Technology Meetup - 3Cape Cod Web Technology Meetup - 3
Cape Cod Web Technology Meetup - 3
Asher Martin
 
Metodologia david ch
Metodologia david chMetodologia david ch
Metodologia david ch
Eduardo David
 
Presentación2
Presentación2Presentación2
Presentación2
ardebrit
 
โครงงานคอมพิวเตอร์
โครงงานคอมพิวเตอร์ โครงงานคอมพิวเตอร์
โครงงานคอมพิวเตอร์
Mark'k Stk
 
Winwin love prezentace
Winwin love prezentaceWinwin love prezentace
Winwin love prezentacefashiontechcz
 
Honza dmitrijev-prezentace fashiontech (2)
Honza dmitrijev-prezentace fashiontech (2)Honza dmitrijev-prezentace fashiontech (2)
Honza dmitrijev-prezentace fashiontech (2)fashiontechcz
 
โครงงานคอมพิวเตอร์ (1)
โครงงานคอมพิวเตอร์ (1)โครงงานคอมพิวเตอร์ (1)
โครงงานคอมพิวเตอร์ (1)
Mark'k Stk
 
Cape Cod Web Technology Meetup - 2
Cape Cod Web Technology Meetup - 2Cape Cod Web Technology Meetup - 2
Cape Cod Web Technology Meetup - 2
Asher Martin
 
โครงงานคอมพิวเตอร์
โครงงานคอมพิวเตอร์โครงงานคอมพิวเตอร์
โครงงานคอมพิวเตอร์
Mark'k Stk
 
Avrora boat
Avrora boatAvrora boat
Avrora boat
Tatjana1989
 
Winwin love prezentace
Winwin love prezentaceWinwin love prezentace
Winwin love prezentacefashiontechcz
 
openMDM5: From a fat client to a scalable, omni-channel architecture
openMDM5: From a fat client to a scalable, omni-channel architectureopenMDM5: From a fat client to a scalable, omni-channel architecture
openMDM5: From a fat client to a scalable, omni-channel architecture
Andreas Benzing
 

Viewers also liked (20)

The Interactive Education Story
The Interactive Education StoryThe Interactive Education Story
The Interactive Education Story
 
Traditional game of bangladesh
Traditional game of bangladeshTraditional game of bangladesh
Traditional game of bangladesh
 
Cape Cod Web Technology Meetup - 3
Cape Cod Web Technology Meetup - 3Cape Cod Web Technology Meetup - 3
Cape Cod Web Technology Meetup - 3
 
Metodologia david ch
Metodologia david chMetodologia david ch
Metodologia david ch
 
telecom engineer
telecom engineertelecom engineer
telecom engineer
 
2015-sdms-foundation-annual-report
2015-sdms-foundation-annual-report2015-sdms-foundation-annual-report
2015-sdms-foundation-annual-report
 
Presentación2
Presentación2Presentación2
Presentación2
 
โครงงานคอมพิวเตอร์
โครงงานคอมพิวเตอร์ โครงงานคอมพิวเตอร์
โครงงานคอมพิวเตอร์
 
Winwin love prezentace
Winwin love prezentaceWinwin love prezentace
Winwin love prezentace
 
Honza dmitrijev-prezentace fashiontech (2)
Honza dmitrijev-prezentace fashiontech (2)Honza dmitrijev-prezentace fashiontech (2)
Honza dmitrijev-prezentace fashiontech (2)
 
โครงงานคอมพิวเตอร์ (1)
โครงงานคอมพิวเตอร์ (1)โครงงานคอมพิวเตอร์ (1)
โครงงานคอมพิวเตอร์ (1)
 
Cape Cod Web Technology Meetup - 2
Cape Cod Web Technology Meetup - 2Cape Cod Web Technology Meetup - 2
Cape Cod Web Technology Meetup - 2
 
โครงงานคอมพิวเตอร์
โครงงานคอมพิวเตอร์โครงงานคอมพิวเตอร์
โครงงานคอมพิวเตอร์
 
Alseth Resume
Alseth ResumeAlseth Resume
Alseth Resume
 
Avrora boat
Avrora boatAvrora boat
Avrora boat
 
MovePlan_Brochure
MovePlan_BrochureMovePlan_Brochure
MovePlan_Brochure
 
Training Certificates
Training CertificatesTraining Certificates
Training Certificates
 
Winwin love prezentace
Winwin love prezentaceWinwin love prezentace
Winwin love prezentace
 
45b8e1ce2
45b8e1ce245b8e1ce2
45b8e1ce2
 
openMDM5: From a fat client to a scalable, omni-channel architecture
openMDM5: From a fat client to a scalable, omni-channel architectureopenMDM5: From a fat client to a scalable, omni-channel architecture
openMDM5: From a fat client to a scalable, omni-channel architecture
 

Similar to Praluent abstract.

lipid lowering therapy heart disease
lipid lowering therapy heart diseaselipid lowering therapy heart disease
lipid lowering therapy heart disease
reygais
 
IMPACT STUDY_12NOV2015
IMPACT STUDY_12NOV2015IMPACT STUDY_12NOV2015
IMPACT STUDY_12NOV2015Kim Kersten
 
Accp hypertension article
Accp hypertension articleAccp hypertension article
Accp hypertension article
abdulghafoor87
 
Genentech’s Dilemma :Avastin VS. Lucentis
Genentech’s Dilemma :Avastin VS. LucentisGenentech’s Dilemma :Avastin VS. Lucentis
Genentech’s Dilemma :Avastin VS. Lucentis
Nejmeddine Jemaa
 
and Brian G. FeaganRoss D. Feldman, Guang Y. Zou, Margaret K.docx
and Brian G. FeaganRoss D. Feldman, Guang Y. Zou, Margaret K.docxand Brian G. FeaganRoss D. Feldman, Guang Y. Zou, Margaret K.docx
and Brian G. FeaganRoss D. Feldman, Guang Y. Zou, Margaret K.docx
rossskuddershamus
 
The Challenges Associated with Evaluating the Cost Benefit of Gene Therapies ...
The Challenges Associated with Evaluating the Cost Benefit of Gene Therapies ...The Challenges Associated with Evaluating the Cost Benefit of Gene Therapies ...
The Challenges Associated with Evaluating the Cost Benefit of Gene Therapies ...
Covance
 
Evaluating the efficacy of different platelet rich plasma regimens for manage...
Evaluating the efficacy of different platelet rich plasma regimens for manage...Evaluating the efficacy of different platelet rich plasma regimens for manage...
Evaluating the efficacy of different platelet rich plasma regimens for manage...
anestesiaudec
 
El ser de seres
El ser de seresEl ser de seres
El ser de seres
ErickMalo2
 
JCP/?PRESENTATION IN A JOURNAL CLUB.....
JCP/?PRESENTATION IN A JOURNAL CLUB.....JCP/?PRESENTATION IN A JOURNAL CLUB.....
JCP/?PRESENTATION IN A JOURNAL CLUB.....
Dr. Ajit Surya Singh
 
The Importance of Biomarkers in Hematology/Oncology Drug Development - Steven...
The Importance of Biomarkers in Hematology/Oncology Drug Development - Steven...The Importance of Biomarkers in Hematology/Oncology Drug Development - Steven...
The Importance of Biomarkers in Hematology/Oncology Drug Development - Steven...
Life Sciences Network marcus evans
 
Samir Rafla. top 10 misconceptions about the new prevention guidelines
Samir Rafla. top 10 misconceptions about the new prevention guidelinesSamir Rafla. top 10 misconceptions about the new prevention guidelines
Samir Rafla. top 10 misconceptions about the new prevention guidelines
Alexandria University, Egypt
 
Lab Results Interpretation for Pharmacist A.Nouri
Lab Results Interpretation for Pharmacist A.NouriLab Results Interpretation for Pharmacist A.Nouri
Lab Results Interpretation for Pharmacist A.Nouri
Ahmed Nouri
 
Protocolo portlad, yale y uwmc
Protocolo portlad, yale y uwmcProtocolo portlad, yale y uwmc
Protocolo portlad, yale y uwmcResidentes1hun
 
Predictors of Change in Adherence Status from 1 Year to the Next Among Patien...
Predictors of Change in Adherence Status from 1 Year to the Next Among Patien...Predictors of Change in Adherence Status from 1 Year to the Next Among Patien...
Predictors of Change in Adherence Status from 1 Year to the Next Among Patien...Vishal Saundankar MS, PGDMM, BS (PHARMACY)
 
COST-EFFECTIVENESS ANALYSIS IN THE MANAGEMENT OF STROKE
COST-EFFECTIVENESS ANALYSIS IN THE MANAGEMENT OF STROKECOST-EFFECTIVENESS ANALYSIS IN THE MANAGEMENT OF STROKE
COST-EFFECTIVENESS ANALYSIS IN THE MANAGEMENT OF STROKE
Dr. Raghavendra Kumar Gunda
 
Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retros...
Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retros...Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retros...
Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retros...
KhalafAlGhamdi
 
Pharmacy Driven Chemotherapy and Monoclonal Antibody Dose-Rounding: A Cost-Sa...
Pharmacy Driven Chemotherapy and Monoclonal Antibody Dose-Rounding: A Cost-Sa...Pharmacy Driven Chemotherapy and Monoclonal Antibody Dose-Rounding: A Cost-Sa...
Pharmacy Driven Chemotherapy and Monoclonal Antibody Dose-Rounding: A Cost-Sa...
ErisTollkuciPharmDBC
 

Similar to Praluent abstract. (20)

lipid lowering therapy heart disease
lipid lowering therapy heart diseaselipid lowering therapy heart disease
lipid lowering therapy heart disease
 
IMPACT STUDY_12NOV2015
IMPACT STUDY_12NOV2015IMPACT STUDY_12NOV2015
IMPACT STUDY_12NOV2015
 
Accp hypertension article
Accp hypertension articleAccp hypertension article
Accp hypertension article
 
final poster
final posterfinal poster
final poster
 
Genentech’s Dilemma :Avastin VS. Lucentis
Genentech’s Dilemma :Avastin VS. LucentisGenentech’s Dilemma :Avastin VS. Lucentis
Genentech’s Dilemma :Avastin VS. Lucentis
 
and Brian G. FeaganRoss D. Feldman, Guang Y. Zou, Margaret K.docx
and Brian G. FeaganRoss D. Feldman, Guang Y. Zou, Margaret K.docxand Brian G. FeaganRoss D. Feldman, Guang Y. Zou, Margaret K.docx
and Brian G. FeaganRoss D. Feldman, Guang Y. Zou, Margaret K.docx
 
The Challenges Associated with Evaluating the Cost Benefit of Gene Therapies ...
The Challenges Associated with Evaluating the Cost Benefit of Gene Therapies ...The Challenges Associated with Evaluating the Cost Benefit of Gene Therapies ...
The Challenges Associated with Evaluating the Cost Benefit of Gene Therapies ...
 
clin news samples
clin news samplesclin news samples
clin news samples
 
Evaluating the efficacy of different platelet rich plasma regimens for manage...
Evaluating the efficacy of different platelet rich plasma regimens for manage...Evaluating the efficacy of different platelet rich plasma regimens for manage...
Evaluating the efficacy of different platelet rich plasma regimens for manage...
 
El ser de seres
El ser de seresEl ser de seres
El ser de seres
 
JCP/?PRESENTATION IN A JOURNAL CLUB.....
JCP/?PRESENTATION IN A JOURNAL CLUB.....JCP/?PRESENTATION IN A JOURNAL CLUB.....
JCP/?PRESENTATION IN A JOURNAL CLUB.....
 
The Importance of Biomarkers in Hematology/Oncology Drug Development - Steven...
The Importance of Biomarkers in Hematology/Oncology Drug Development - Steven...The Importance of Biomarkers in Hematology/Oncology Drug Development - Steven...
The Importance of Biomarkers in Hematology/Oncology Drug Development - Steven...
 
Samir Rafla. top 10 misconceptions about the new prevention guidelines
Samir Rafla. top 10 misconceptions about the new prevention guidelinesSamir Rafla. top 10 misconceptions about the new prevention guidelines
Samir Rafla. top 10 misconceptions about the new prevention guidelines
 
Lab Results Interpretation for Pharmacist A.Nouri
Lab Results Interpretation for Pharmacist A.NouriLab Results Interpretation for Pharmacist A.Nouri
Lab Results Interpretation for Pharmacist A.Nouri
 
Protocolo portlad, yale y uwmc
Protocolo portlad, yale y uwmcProtocolo portlad, yale y uwmc
Protocolo portlad, yale y uwmc
 
Predictors of Change in Adherence Status from 1 Year to the Next Among Patien...
Predictors of Change in Adherence Status from 1 Year to the Next Among Patien...Predictors of Change in Adherence Status from 1 Year to the Next Among Patien...
Predictors of Change in Adherence Status from 1 Year to the Next Among Patien...
 
COST-EFFECTIVENESS ANALYSIS IN THE MANAGEMENT OF STROKE
COST-EFFECTIVENESS ANALYSIS IN THE MANAGEMENT OF STROKECOST-EFFECTIVENESS ANALYSIS IN THE MANAGEMENT OF STROKE
COST-EFFECTIVENESS ANALYSIS IN THE MANAGEMENT OF STROKE
 
VIPER BP
VIPER BPVIPER BP
VIPER BP
 
Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retros...
Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retros...Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retros...
Proton Pump Inhibitors and Risk of Acute and Chronic Kidney Disease: A Retros...
 
Pharmacy Driven Chemotherapy and Monoclonal Antibody Dose-Rounding: A Cost-Sa...
Pharmacy Driven Chemotherapy and Monoclonal Antibody Dose-Rounding: A Cost-Sa...Pharmacy Driven Chemotherapy and Monoclonal Antibody Dose-Rounding: A Cost-Sa...
Pharmacy Driven Chemotherapy and Monoclonal Antibody Dose-Rounding: A Cost-Sa...
 

Recently uploaded

Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
KafrELShiekh University
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
Savita Shen $i11
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
MedicoseAcademics
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
Anujkumaranit
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
MedicoseAcademics
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
addon Scans
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
LanceCatedral
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
i3 Health
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
Sujoy Dasgupta
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
SumeraAhmad5
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
DrSathishMS1
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
Shweta
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Savita Shen $i11
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Dr Jeenal Mistry
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
Rohit chaurpagar
 
Surgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptxSurgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptx
jval Landero
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
aljamhori teaching hospital
 

Recently uploaded (20)

Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
 
The Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of IIThe Normal Electrocardiogram - Part I of II
The Normal Electrocardiogram - Part I of II
 
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptxMaxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
Maxilla, Mandible & Hyoid Bone & Clinical Correlations by Dr. RIG.pptx
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
 
Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...Couples presenting to the infertility clinic- Do they really have infertility...
Couples presenting to the infertility clinic- Do they really have infertility...
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
 
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model SafeSurat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
 
Antiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptxAntiulcer drugs Advance Pharmacology .pptx
Antiulcer drugs Advance Pharmacology .pptx
 
Surgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptxSurgical Site Infections, pathophysiology, and prevention.pptx
Surgical Site Infections, pathophysiology, and prevention.pptx
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
 

Praluent abstract.

  • 1. A Budget Impact Analysis of Alirocumab in Heterozygous Familial Hypercholesterolemia Treatment Background: Heterozygous familial hypercholesterolemia (HeFH) is a rare genetic disease affecting an estimated 1:500 people. The disease results in LDL levels far above the recommended range which results in an increased risk of adverse cardiac events. Current standard of care treatment options such as high intensity statins and ezetimibe, only achieve recommended LDL levels, instituted by ATP III guidelines, in 20% of treated patients.PKSC9 inhibitors are a new class of effective but highly priced drug therapy recently approved to treat HeFH that have been shown to be safe and more effective in lowering LDL to guideline recommended levels. Objective: The aim of this study was to prepare a budget impact analysis based on pharmacy drug costs only, as outcomes data was not yet available, to assist a commercial health plan in evaluating the 1 year financial impact of the introduction of Alirocumab to their formulary for the approved treatment of Heterozygous Familial Hypercholesterolemia. Methods: A budget impact analysis was developed for a hypothetical commercial US health plan consisting of 1 million members ages 18-64 years old. Data was inputted into a model created in an excel spreadsheet. Model inputs included disease prevalence reported from the center for disease control, target population, drug costs obtained from whole sale acquisition costs from Red Book (accessed June 2015), and estimated drug market shares based on treatment guidelines and efficacy data. Costs were reported in 2015 US dollars as total overall costs, price per member per month (PMPM), and price per treated member per month (PTMPM). A One-Way sensitivity analysis was performed on the study assumptions which included the costs of the new treatment and the already established medications for treatment, and the percentage of patients treated. Results: An estimated 1,600 of the hypothetical 1,000,000 enrollees were projected to be treated for heterozygous familial hypercholesterolemia. It was estimated based on current treatment data, that 70% or 1,120 enrollees would be placed on Alirocumab due to lack of meeting ATP III LDL goals by current basic standard of care treatments. Statistical analysis was done on drug costs only. It was found that the addition of Alricoumab as a treatment option resulted in a total drug spend of $11,712,160 over a 1 year time horizon. The estimated PMPM for all covered lives was $0.976 while the estimated PTMPM for all covered lives was $7,320. Based on the sensitivity analysis, the PMPM after the introduction of Alirocumab had a range $0.883-$1.074 and the range for PTMPM was $6,954-$7,686.
  • 2. Conclusion: Alirocumab has been proven by multiple double blind, placebo, controlled clinical trials to be safe and effective with 94% of patients treated achieving LDL levels less than 100mg/dL. It is an effective treatment option for patients who are not achieving their LDL goals on a high intensity statin with or without ezetimibe. However, the high projected cost of $10,000 for a one year of treatment with alirocumab will need to be heavily weighed when making formulary decisions. A better analysis will be able to be formed when data from the ODYSSEY OUTCOMES trial is released in 2017.
  • 3. Bibliography Eur Heart J. 2013 Dec 1; 34(45): 3478–3490. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3844152/ "Gene Mutations Linked to Statin Resistance." <i>- Duke Medicine</i>. Duke Medicine News and Communications, 4 Aug. 2010. Web. 01 July 2015. FDA advisory committee briefing document PraluentTM (alirocumab). Endocrinologic and Metabolic Drugs Advisory Committee. http://amcp.edossiers.com/students/search/ext_preview.aspx?ModuleID=5100&ItemID= 1984282&DrugID=6755&From=RES June 9, 2015 Kastelein, John J. P., Jennifer G. Robinson, Michel Farnier, Michel Krempf, Gisle Langslet, Christelle Lorenzato, Daniel A. Gipe, and Marie T. Baccara-Dinet. "Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia Not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies." Cardiovascular Drugs and Therapy. Springer US, 20 May 2014. Web. 01 July 2015. Pijlman, A.H. et al. “Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands Atherosclerosis , Volume 209 , Issue 1 , 189 – 194 Red Book Online, Micromedex Solutions. Accessed June, 2015 Straton, Tracy. "Payers Fret about the next Drug Doomsday: Pricey PCSK9 Cholesterol Meds." FiercePharmaMarketing. Fierce Pharma Marketing, 7 May 2014. Web. 01 July 2015.